Logo

SGMT

Sagimet Biosciences Inc.

SGMT

Sagimet Biosciences Inc. • NASDAQ
$7.22 ▲ 1.98% (+0.14)
Market Cap $223.83 M
52w High $11.41
52w Low $1.73
Dividend Yield 0%
P/E -4.06
Volume 211.87K
Outstanding Shares 31.00M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $14.334M ▲ $-12.908M ▼ 0% $-0.4 ▼ $-12.908M ▼
Q2-2025 $0 $11.925M ▼ $-10.386M ▲ 0% $-0.32 ▲ $-11.925M ▲
Q1-2025 $0 $19.865M ▲ $-18.176M ▼ 0% $-0.56 ▼ $-19.865M ▼
Q4-2024 $0 $18.195M ▲ $-16.201M ▼ 0% $-0.5 ▼ $-16.201M ▲
Q3-2024 $0 $16.902M $-14.619M 0% $-0.45 $-16.902M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $116.693M ▼ $128.401M ▼ $9.146M ▲ $119.255M ▼
Q2-2025 $125.407M ▼ $137.407M ▼ $7.247M ▲ $130.16M ▼
Q1-2025 $144.569M ▼ $146.172M ▼ $7.18M ▲ $138.992M ▼
Q4-2024 $151.25M ▼ $160.259M ▼ $4.454M ▲ $155.805M ▼
Q3-2024 $152.486M $174.775M $4.092M $170.683M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-12.908M ▼ $-10.18M ▼ $75K ▲ $274K ▲ $-9.831M ▲ $-10.18M ▼
Q2-2025 $-10.386M ▲ $-9.101M ▲ $-13.29M ▼ $1K ▲ $-22.39M ▼ $-9.101M ▲
Q1-2025 $-18.176M ▼ $-14.536M ▼ $3.413M ▼ $0 $-11.123M ▼ $-14.536M ▼
Q4-2024 $-16.201M ▼ $-11.024M ▲ $9.85M ▲ $0 $-1.174M ▲ $-11.024M ▲
Q3-2024 $-14.619M $-19.569M $624K $0 $-18.945M $-19.569M

Five-Year Company Overview

Income Statement

Income Statement Sagimet is a classic early‑stage biotech story: no product revenue yet and steady research‑driven losses. The income statement shows a consistent pattern of spending more than it earns, which is normal for a company still in clinical development. Losses have gradually increased over time as projects progress, but the scale remains relatively small compared with commercial‑stage peers. The key takeaway is that the business is entirely dependent on external funding while it works to turn its scientific programs into potential future products.

Balance Sheet

Balance Sheet The balance sheet is simple and lean. Assets are mostly cash and equivalents, with very little in the way of physical or long‑lived assets. There is no financial debt, which reduces balance‑sheet risk but also underlines that the company relies on equity funding. Equity has increased in recent years as new capital has come in, improving the cushion to support ongoing trials, but the overall asset base is still modest. The company’s financial strength ultimately depends on its ability to keep raising capital until it can generate meaningful revenue.

Cash Flow

Cash Flow Cash flow reflects a controlled but persistent cash burn. Operating cash outflows line up with the income statement losses, showing that most cash is being used for research, clinical trials, and corporate overhead rather than for factories or equipment. Capital spending is negligible, so free cash flow is essentially the operating cash burn. The pattern suggests careful spending but also highlights that Sagimet will likely need periodic infusions of new cash to maintain its development programs.

Competitive Edge

Competitive Edge Sagimet is trying to carve out a focused niche in metabolic and fibrotic diseases by targeting the FASN pathway, especially in MASH. Its lead drug candidate has a differentiated mechanism, is taken orally once a day, and has received an expedited FDA designation, all of which strengthen its positioning. At the same time, the MASH field is becoming crowded, with large pharma and other biotechs already advancing different types of therapies. Sagimet’s edge rests on being early in FASN inhibition, having intellectual property protection, and potentially combining well with other drugs, but it still faces intense competition and significant clinical and regulatory uncertainty.

Innovation and R&D

Innovation and R&D Innovation is the core of the story. Sagimet is building a platform around FASN inhibition, starting with its lead candidate for MASH and branching into acne, cancer, and a second‑generation molecule. The science aims to attack root metabolic drivers rather than just symptoms, which, if successful, could translate into broad medical use. The pipeline is still mostly in clinical and preclinical stages, so outcomes are uncertain, but the company is clearly investing to turn its FASN know‑how into a family of programs rather than a single‑asset bet.

Summary

Sagimet is an early‑stage, pre‑revenue biotech with a focused scientific strategy and a narrow but potentially powerful technology platform. Financially, it has no operating revenue, runs predictable research‑driven losses, holds a modest but meaningful cash cushion, and avoids debt, but it remains dependent on new funding over time. Strategically, it sits in a large, competitive disease area with a differentiated mechanism and supportive regulatory signals, yet faces the usual biotech risks around clinical results, approvals, and commercial execution. Overall, this is a high‑uncertainty, development‑stage profile where future value depends heavily on the success of a few key trials and the company’s ability to sustain funding through them.

NEWS

November 20, 2025 · 7:00 AM UTC

Sagimet Biosciences to Participate in the 8th Annual Evercore ISI Healthcare Conference

Read more

November 10, 2025 · 7:00 AM UTC

Sagimet Biosciences Presents Two Denifanstat Posters at AASLD—The Liver Meeting® 2025

Read more

October 24, 2025 · 7:00 AM UTC

Denifanstat Achieved All Endpoints in the Treatment of Moderate to Severe Acne in Phase 3 Clinical Trial in Acne in China: A Presentation at the 2025 Fall Clinical Dermatology Conference

Read more

October 14, 2025 · 7:00 AM UTC

Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences

Read more

October 14, 2025 · 6:00 AM UTC

Ascletis Completes Denifanstat (ASC40) Pre-NDA Consultation with China National Medical Products Administration

Read more